Sefiksim etkileşimleri

sefalosporin sınıfından Sefiksim (Suprax) için dizinlediğimiz FDA etiketlerinde ve bilgi sayfalarında 50 belgelenmiş etkileşim var: 23 majör, 25 orta, 2 minör ve bir etiketin anlamlı etkileşim olmadığını bildirdiği 0 çift. Aşağıdaki her kayıt, dayandığı cümleyi alıntılar. Bu ilaç sayfası bir başlangıç noktasıdır; sizin durumunuz için verilmiş bir hüküm değildir.

Sefiksim nasıl görünür

5 sürümün tümü
Sefiksim 400 mg kapsül: pembe, 21 mm, bir yüzünde CFX, diğer yüzünde 400 baskısı var.
CFX / 400
400 mg · pembe · kapsül · 21 mm
Health Department, Oklahom…
Sefiksim 400 mg kapsül: pembe, 21 mm, bir yüzünde CMI, diğer yüzünde 400 baskısı var.
CMI / 400
400 mg · pembe · kapsül · 21 mm
Aurobindo
Sefiksim 400 mg kapsül: pembe ve pembe, 22 mm, bir yüzünde LU, diğer yüzünde U43 baskısı var.
LU / U43
400 mg · pembe ve pembe · kapsül · 22 mm
Lupin
Sefiksim 400 mg kapsül: pembe ve pembe, 26 mm, bir yüzünde LU, diğer yüzünde U43 baskısı var.
LU / U43
400 mg · pembe ve pembe · kapsül · 26 mm
Lupin

Çizimler, FDA etiketlerindeki ürün bilgilerinden oluşturulmuştur: renk, şekil, boyut ve baskı. 5 firmaya ait 5 belgelenmiş sürüm.

Etikete göre etkileşimler

Majör etkileşimler (23)

  • Amoksisilinpenisilin antibiyotikMajör

    AMOXIL is contraindicated in patients who have experienced a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to AMOXIL or to other β-lactam antibacterial drugs (e.g., penicillins and cephalosporins). (Amoksisilin etiketi, Kontrendikasyonlar)

  • Amoksisilin ve klavulanatpenisilin antibiyotikMajör

    History of a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to AUGMENTIN or to other beta‑lactams (e.g., penicillins or cephalosporins). (Amoksisilin ve klavulanat etiketi, Kontrendikasyonlar)

  • Ampisilinpenisilin antibiyotikMajör

    CONTRAINDICATIONS The use of Ampicillin is contraindicated in individuals with a history of serious hypersensitivity reactions (e.g., anaphylaxis or Stevens-Johnson syndrome) to ampicillin or to other beta-lactam antibacterial drugs. (Ampisilin etiketi, Kontrendikasyonlar)

  • Ampisilin ve sulbaktampenisilin antibiyotikMajör

    CONTRAINDICATIONS The use of UNASYN is contraindicated in individuals with a history of serious hypersensitivity reactions (e.g., anaphylaxis or Stevens-Johnson syndrome) to ampicillin, sulbactam or to other beta-lactam antibacterial drugs (e.g., penicillins and cephalosporins). (Ampisilin ve sulbaktam etiketi, Kontrendikasyonlar)

  • ErtapenemantibiyotikMajör

    INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (Ertapenem etiketi, Kontrendikasyonlar)

  • İmipenem ve silastatinantibiyotikMajör

    Hypersensitivity Reactions: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with beta-lactams. (İmipenem ve silastatin etiketi, Uyarılar ve önlemler)

  • Nafsilinpenisilin antibiyotikMajör

    WARNINGS Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibacterial drugs. (Nafsilin etiketi, Uyarılar)

  • Piperasilin ve tazobaktampenisilin antibiyotikMajör

    Piperacillin and Tazobactam for Injection and Sodium Chloride Injection is contraindicated in patients with a history of allergic reactions to any of the penicillins, cephalosporins, or betalactamase inhibitors. (Piperasilin ve tazobaktam etiketi, Kontrendikasyonlar)

  • SefadroksilsefalosporinMajör

    Contraindicated in patients with known allergy to cefixime or other cephalosporins. (Sefiksim etiketi, Kontrendikasyonlar)

  • SefaklorsefalosporinMajör

    Contraindicated in patients with known allergy to cefixime or other cephalosporins. (Sefiksim etiketi, Kontrendikasyonlar)

  • SefaleksinsefalosporinMajör

    Contraindicated in patients with known allergy to cefixime or other cephalosporins. (Sefiksim etiketi, Kontrendikasyonlar)

  • SefazolinsefalosporinMajör

    Contraindicated in patients with known allergy to cefixime or other cephalosporins. (Sefiksim etiketi, Kontrendikasyonlar)

  • SefdinirsefalosporinMajör

    Contraindicated in patients with known allergy to cefixime or other cephalosporins. (Sefiksim etiketi, Kontrendikasyonlar)

  • SefepimsefalosporinMajör

    Contraindicated in patients with known allergy to cefixime or other cephalosporins. (Sefiksim etiketi, Kontrendikasyonlar)

  • SefoksitinsefalosporinMajör

    Contraindicated in patients with known allergy to cefixime or other cephalosporins. (Sefiksim etiketi, Kontrendikasyonlar)

  • SefotaksimsefalosporinMajör

    Contraindicated in patients with known allergy to cefixime or other cephalosporins. (Sefiksim etiketi, Kontrendikasyonlar)

  • SefotetansefalosporinMajör

    Contraindicated in patients with known allergy to cefixime or other cephalosporins. (Sefiksim etiketi, Kontrendikasyonlar)

  • SefpodoksimsefalosporinMajör

    Contraindicated in patients with known allergy to cefixime or other cephalosporins. (Sefiksim etiketi, Kontrendikasyonlar)

  • SefprozilsefalosporinMajör

    Contraindicated in patients with known allergy to cefixime or other cephalosporins. (Sefiksim etiketi, Kontrendikasyonlar)

  • SeftarolinsefalosporinMajör

    Contraindicated in patients with known allergy to cefixime or other cephalosporins. (Sefiksim etiketi, Kontrendikasyonlar)

  • SeftazidimsefalosporinMajör

    Contraindicated in patients with known allergy to cefixime or other cephalosporins. (Sefiksim etiketi, Kontrendikasyonlar)

  • SeftriaksonsefalosporinMajör

    Contraindicated in patients with known allergy to cefixime or other cephalosporins. (Sefiksim etiketi, Kontrendikasyonlar)

  • SefuroksimsefalosporinMajör

    Contraindicated in patients with known allergy to cefixime or other cephalosporins. (Sefiksim etiketi, Kontrendikasyonlar)

Orta düzey etkileşimler (25)

  • ApiksabanantikoagülanOrta

    Those at risk include patients with renal or hepatic impairment, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Sefiksim etiketi, Uyarılar ve önlemler)

  • ArgatrobanantikoagülanOrta

    Those at risk include patients with renal or hepatic impairment, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Sefiksim etiketi, Uyarılar ve önlemler)

  • AztreonamantibiyotikOrta

    Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Aztreonam etiketi, Uyarılar ve önlemler)

  • BivalirudinantikoagülanOrta

    Those at risk include patients with renal or hepatic impairment, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Sefiksim etiketi, Uyarılar ve önlemler)

  • DabigatranantikoagülanOrta

    Those at risk include patients with renal or hepatic impairment, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Sefiksim etiketi, Uyarılar ve önlemler)

  • Dikloksasilinpenisilin antibiyotikOrta

    If this product is to be given to penicillin-sensitive patients, caution should be exercised because cross hypersensitivity among beta-lactam antibacterial drugs has been clearly documented and may occur in up to 10% of patients with a history of penicillin allergy. (Sefiksim etiketi, Uyarılar ve önlemler)

  • EdoksabanantikoagülanOrta

    Those at risk include patients with renal or hepatic impairment, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Sefiksim etiketi, Uyarılar ve önlemler)

  • EnoksaparinantikoagülanOrta

    Those at risk include patients with renal or hepatic impairment, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Sefiksim etiketi, Uyarılar ve önlemler)

  • Etakrinik asitkıvrım (loop) diüretiğiOrta

    Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (Etakrinik asit etiketi, İlaç etkileşimleri)

  • Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated. (Sefiksim etiketi, Uyarılar ve önlemler)

  • FondaparinuksantikoagülanOrta

    Those at risk include patients with renal or hepatic impairment, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Sefiksim etiketi, Uyarılar ve önlemler)

  • Furosemidkıvrım (loop) diüretiğiOrta

    Cephalosporin Furosemide can increase the risk of cephalosporin-induced nephrotoxicity even in the setting of minor or transient renal impairment. (Furosemid etiketi, İlaç etkileşimleri)

  • GentamisinaminoglikozidOrta

    Increased nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporins. (Gentamisin etiketi, İlaç etkileşimleri)

  • HeparinantikoagülanOrta

    Those at risk include patients with renal or hepatic impairment, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Sefiksim etiketi, Uyarılar ve önlemler)

  • K vitaminiVitamin ve mineralOrta

    Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated. (Sefiksim etiketi, Uyarılar ve önlemler)

  • KarbamazepinantikonvülsanOrta

    Drug monitoring may be of assistance in detecting alterations in carbamazepine plasma concentrations. (Sefiksim etiketi, İlaç etkileşimleri)

  • MikofenolatimmünosüpresanOrta

    Examples Cyclosporine A, trimethoprim/sulfamethoxazole, bile acid sequestrants (cholestyramine), rifampin as well as aminoglycoside, cephalosporin, fluoroquinolone and penicillin classes of antimicrobials Drugs Modulating Glucuronidation Clinical Impact Concomitant use with drugs inducing glucuronidation decreases MPA systemic exposure, potentially reducing mycophenolate… (Mikofenolat etiketi, İlaç etkileşimleri)

  • Oksasilinpenisilin antibiyotikOrta

    If this product is to be given to penicillin-sensitive patients, caution should be exercised because cross hypersensitivity among beta-lactam antibacterial drugs has been clearly documented and may occur in up to 10% of patients with a history of penicillin allergy. (Sefiksim etiketi, Uyarılar ve önlemler)

  • Penisilin Gpenisilin antibiyotikOrta

    If this product is to be given to penicillin-sensitive patients, caution should be exercised because cross hypersensitivity among beta-lactam antibacterial drugs has been clearly documented and may occur in up to 10% of patients with a history of penicillin allergy. (Sefiksim etiketi, Uyarılar ve önlemler)

  • Penisilin Vpenisilin antibiyotikOrta

    If this product is to be given to penicillin-sensitive patients, caution should be exercised because cross hypersensitivity among beta-lactam antibacterial drugs has been clearly documented and may occur in up to 10% of patients with a history of penicillin allergy. (Sefiksim etiketi, Uyarılar ve önlemler)

  • Drug Interactions When probenecid is used to elevate plasma concentrations of penicillin or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (Probenesid etiketi, İlaç etkileşimleri)

  • DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

  • Drug Interactions Protamine sulfate has been shown to be incompatible with certain antibiotics, including several of the cephalosporins and penicillins (see DOSAGE AND ADMINISTRATION ). (Protamin etiketi, Önlemler)

  • RivaroksabanantikoagülanOrta

    Those at risk include patients with renal or hepatic impairment, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Sefiksim etiketi, Uyarılar ve önlemler)

  • VarfarinantikoagülanOrta

    Those at risk include patients with renal or hepatic impairment, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Sefiksim etiketi, Uyarılar ve önlemler)

Minör değinmeler (2)

  • MeropenemantibiyotikMinör

    Before initiating therapy with Meropenem for injection, it is important to inquire about previous hypersensitivity reactions to penicillins, cephalosporins, other β-lactams, and other allergens. (Meropenem etiketi, Uyarılar ve önlemler)

  • NitroprussidvazodilatörMinör

    Drug/Laboratory Test Interactions A false-positive reaction for ketones in the urine may occur with tests using nitroprusside but not with those using nitroferricyanide. (Sefiksim etiketi, İlaç etkileşimleri)

Kullandığınız her şeyi Sefiksim ile karşılaştırın. Tüm listenizi ekleyin; her çift tek seferde kontrol edilir.

Sorgulama aracında aç

Tıbbi tavsiye değildir. Şiddet derecesi sizin koşullarınızı değil, etiketin ifadesini yansıtır. “Majör” işareti gözetim altında olağan bir uygulama olabilir, “minör” işareti ise yüksek dozlarda önem kazanabilir. Bir eczacıya danışın.